The takeaway
Cue Biopharma shows a pronounced seasonal pattern over 8 years of data — strongest in October (+10.8%) and softest in June (−12.3%).
Right now
In July, the stock has fallen 38% of years, averaging −6.0%, roughly 8.2 pts behind the S&P 500.
The full picture
Cue Biopharma's most dependable month has been October, higher in 4 of 8 years; June has been its least reliable, up just 25% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 |
Month by month
The stock's clearest edge over the S&P 500 lands in October (+9.7 pts); it has trailed the market most in June (−12.5 pts).
“vs S&P” is Cue Biopharma’s average for a month minus the S&P 500’s average for that same month — isolating Cue Biopharma’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, October has closed higher 60% of the time versus 50% across the last 8 years — the pattern is strengthening.
Figures are the typical (median) October return and how often it rose — the last 5 years versus the last 8(the heatmap’s default window). This verdict stays anchored to that 8-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
There's little seasonal signal to find. No month pulls clear: October is nominally the steadiest, yet at 4 of 8 Octobers it's barely better than a coin toss.
Its roughest month on record was a −48.7% December in 2025 — a reminder of how hard even a seasonal name can fall.
If anything it has sharpened recently — the last five Octobers run ahead of the earlier years.
The honest read is that the calendar is close to noise here — better treated as background than a reason to act. With a short 8-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (October), its worst (June), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2018 its best month (October, +10.8%) has run well ahead of its worst (June, −12.3%) — the heatmap above shows how steady that gap has been year to year.
October has been the strongest, averaging +10.8% and closing higher in 4 of 8 years since 2018.
It's the weakest, averaging −12.3% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade